The prognostic value of CD44 isoform expression in endometrial cancer
1998

The Role of CD44 Isoforms in Endometrial Cancer

Sample size: 156 publication Evidence: low

Author Information

Author(s): C Tempferl, G Haeusler, A Kaider, L Hefler, E Hanzal, A Reinthaller, G Breitenecker, Ch Kainz

Primary Institution: University of Vienna Medical School

Hypothesis

Is CD44 isoform expression a prognostic factor in endometrial cancer?

Conclusion

The expression of CD44 isoforms is not an adverse predictive factor in endometrial cancer.

Supporting Evidence

  • CD44 isoforms were detected in 26% to 31% of tumor samples.
  • CD44v6 expression showed an association with shortened overall survival.
  • Multivariate analysis revealed CD44v6 not to be an independent prognostic factor.

Takeaway

This study looked at a protein called CD44 in cancer samples to see if it could help predict how patients would do. They found it doesn't really help with that.

Methodology

Immunohistochemistry was used to analyze CD44 isoform expression in 156 endometrial cancer specimens.

Limitations

The study did not include lymph node status in the analysis due to the study period.

Participant Demographics

Median age of patients was 59 years, with a range of 48-71 years.

Statistical Information

P-Value

0.06

Confidence Interval

0.97-8.1

Statistical Significance

p=0.06

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication